Alanna Weisman

Dr. Weisman's research program examines how healthcare systems can better deliver evidence-based diabetes care, with a particular focus on access to diabetes technologies such as continuous glucose monitoring, insulin pumps, and automated insulin delivery systems. Using large-scale population-based health data, electronic medical records, clinical registries, qualitative methods, and implementation science approaches, she studies real-world outcomes in type 1 diabetes, identifies inequities in care, and develops interventions to improve equitable access to effective therapies.
Dr. Weisman has established a nationally recognized research program that spans epidemiology, health services research, implementation science, and patient-oriented research. Her work has informed Diabetes Canada Clinical Practice Guidelines, contributed to health policy and advocacy initiatives, and helped shape national discussions regarding equitable access to diabetes technologies. She leads EQUAT1D (Equitable Uptake and Appropriate Use of Technologies for Adults with Type 1 Diabetes), a multi-phase research program focused on understanding and addressing barriers to diabetes technology use among socially disadvantaged populations.
Dr. Weisman has published more than 40 peer-reviewed manuscripts and has received funding from the Canadian Institutes of Health Research, Diabetes Canada, Breakthrough T1D Canada, and the Government of Ontario. She is committed to integrating equity, diversity, inclusion, and meaningful patient partnership throughout the research process to ensure that advances in diabetes care benefit all people living with type 1 diabetes.